These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30892934)

  • 1. Expansion of regulatory T cells using low-dose interleukin-2 attenuates hypertension in an experimental model of systemic lupus erythematosus.
    Taylor EB; Sasser JM; Maeda KJ; Ryan MJ
    Am J Physiol Renal Physiol; 2019 Nov; 317(5):F1274-F1284. PubMed ID: 30892934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human recombinant relaxin-2 does not attenuate hypertension or renal injury but exacerbates vascular dysfunction in a female mouse model of SLE.
    Wolf VL; Phillips TL; Taylor EB; Sasser JM; Ryan MJ
    Am J Physiol Heart Circ Physiol; 2019 Aug; 317(2):H234-H242. PubMed ID: 31125285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Cell Depletion Attenuates Hypertension in an Experimental Model of Autoimmune Disease.
    Taylor EB; Barati MT; Powell DW; Turbeville HR; Ryan MJ
    Hypertension; 2018 Apr; 71(4):719-728. PubMed ID: 29378858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.
    von Spee-Mayer C; Siegert E; Abdirama D; Rose A; Klaus A; Alexander T; Enghard P; Sawitzki B; Hiepe F; Radbruch A; Burmester GR; Riemekasten G; Humrich JY
    Ann Rheum Dis; 2016 Jul; 75(7):1407-15. PubMed ID: 26324847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin attenuates autoimmunity and renal injury in an experimental model of systemic lupus erythematosus.
    Dent EL; Taylor EB; Turbeville HR; Ryan MJ
    Physiol Rep; 2020 Jul; 8(13):e14501. PubMed ID: 32652896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide treatment for hypertension and renal injury in an experimental model of systemic lupus erythematosus.
    Wolf VL; Taylor EB; Ryan MJ
    Physiol Rep; 2019 May; 7(10):e14059. PubMed ID: 31124322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppression With Mycophenolate Mofetil Attenuates Hypertension in an Experimental Model of Autoimmune Disease.
    Taylor EB; Ryan MJ
    J Am Heart Assoc; 2017 Feb; 6(3):. PubMed ID: 28242635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure and albuminuria in a female mouse model of systemic lupus erythematosus: impact of long-term high salt consumption.
    Dent EL; Broome HJ; Sasser JM; Ryan MJ
    Am J Physiol Regul Integr Comp Physiol; 2020 Oct; 319(4):R448-R454. PubMed ID: 32813539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of Murine Lupus by CD4+ and CD8+ Treg Cells Induced by T Cell-Targeted Nanoparticles Loaded With Interleukin-2 and Transforming Growth Factor β.
    Horwitz DA; Bickerton S; Koss M; Fahmy TM; La Cava A
    Arthritis Rheumatol; 2019 Apr; 71(4):632-640. PubMed ID: 30407752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal hemodynamic changes in a female mouse model of systemic lupus erythematosus.
    Dent EL; Taylor EB; Sasser JM; Ryan MJ
    Am J Physiol Renal Physiol; 2020 May; 318(5):F1074-F1085. PubMed ID: 32150445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD3 antibody therapy attenuates the progression of hypertension in female mice with systemic lupus erythematosus.
    Mathis KW; Taylor EB; Ryan MJ
    Pharmacol Res; 2017 Jun; 120():252-257. PubMed ID: 28400152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-2 Therapy Diminishes Renal Inflammation and the Activity of Kidney-Infiltrating CD4+ T Cells in Murine Lupus Nephritis.
    Rose A; von Spee-Mayer C; Kloke L; Wu K; Kühl A; Enghard P; Burmester GR; Riemekasten G; Humrich JY
    Cells; 2019 Oct; 8(10):. PubMed ID: 31614462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosus.
    Lyu MA; Tang X; Khoury JD; Raso MG; Huang M; Zeng K; Nishimoto M; Ma H; Sadeghi T; Flowers CR; Parmar S
    Front Immunol; 2023; 14():1217121. PubMed ID: 37736101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients.
    Zhao C; Chu Y; Liang Z; Zhang B; Wang X; Jing X; Hao M; Wang Y; An J; Zhang X; Sun L; Chen J
    BMC Immunol; 2019 Sep; 20(1):32. PubMed ID: 31484501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-Edged Sword: Interleukin-2 Promotes T Regulatory Cell Differentiation but Also Expands Interleukin-13- and Interferon-γ-Producing CD8
    Kato H; Perl A
    Front Immunol; 2021; 12():635531. PubMed ID: 33763079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoring regulation - IL-2 therapy in systemic lupus erythematosus.
    Humrich JY; Riemekasten G
    Expert Rev Clin Immunol; 2016 Nov; 12(11):1153-1160. PubMed ID: 27283871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-Dose IL-2 in the Treatment of Lupus.
    Mizui M; Tsokos GC
    Curr Rheumatol Rep; 2016 Nov; 18(11):68. PubMed ID: 27734211
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Toral M; Robles-Vera I; Romero M; de la Visitación N; Sánchez M; O'Valle F; Rodriguez-Nogales A; Gálvez J; Duarte J; Jiménez R
    FASEB J; 2019 Sep; 33(9):10005-10018. PubMed ID: 31173526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension and impaired vascular function in a female mouse model of systemic lupus erythematosus.
    Ryan MJ; McLemore GR
    Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R736-42. PubMed ID: 16971374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4
    Peixoto TV; Carrasco S; Botte DAC; Catanozi S; Parra ER; Lima TM; Ugriumov N; Soriano FG; de Mello SBV; Rodrigues CM; Goldenstein-Schainberg C
    Adv Rheumatol; 2019 Jul; 59(1):30. PubMed ID: 31340848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.